BioCardia, Inc.
Income Statement
| Line Item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $3.0K | $55.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $1.1M | $936.0K | $1.4M | $1.5M | $1.4M | $931.0K | $800.0K | $1.2M |
| SG&A Expense | $885.0K | $552.0K | $683.0K | $1.2M | $906.0K | $825.0K | $852.0K | $1.1M |
| Operating Income | $-2.0M | $-1.5M | $-2.1M | $-2.7M | $-2.3M | $-1.8M | $-1.6M | $-2.3M |
| Operating Margin | — | — | — | — | — | — | -54,966.7% | -4,136.4% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-2.0M | $-1.5M | $-2.0M | $-2.7M | $-2.3M | $-1.7M | $-1.6M | $-2.3M |
| Net Margin | — | — | — | — | — | — | -54,866.7% | -4,121.8% |
| EPS (Basic) | $0.00 | $-0.12 | $-0.20 | $-0.30 | $-0.03 | $-0.31 | $-0.44 | $-0.68 |
| EPS (Diluted) | — | — | $-0.20 | $-0.30 | — | — | — | — |
| Shares Outstanding (Basic) | 6.7M | 12.6M | 10.1M | 9.3M | 5.5M | 5.7M | 3.8M | 3.4M |
| Shares Outstanding (Diluted) | 6.7M | 12.6M | 10.1M | 9.3M | 5.5M | 5.7M | 3.8M | 3.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |